A 52-year-old woman with a history of gastroesophageal reflux disease (GERD) for 15 years undergoes upper endoscopy for surveillance. Endoscopic biopsies from the distal esophagus show replacement of the normal stratified squamous epithelium with columnar epithelium containing intestinal-type glands with goblet cells. The mucosa appears grossly normal without visible ulceration or nodularity. Which investigation is most appropriate to assess the presence and grade of dysplasia in this Barrett's esophagus?

Explanation

## Investigation of Choice for Dysplasia Assessment in Barrett's Esophagus ### Clinical Scenario The patient has Barrett's esophagus (metaplasia of esophageal squamous epithelium to columnar epithelium with intestinal metaplasia). The critical next step is to assess for dysplasia, which is the **precancerous lesion** that determines surveillance intensity and treatment strategy. ### Why Chromoendoscopy with Targeted Biopsies is the Gold Standard **Key Point:** Chromoendoscopy (using vital dyes such as methylene blue or indigo carmine) combined with **targeted biopsies and histopathological dysplasia grading** is the **most appropriate investigation** for detecting and grading dysplasia in Barrett's esophagus. It: - **Enhances visualization**: highlights areas of dysplasia that may be missed on white-light endoscopy - **Enables targeted sampling**: biopsies are directed to suspicious areas, improving diagnostic yield - **Provides morphologic diagnosis**: histology grades dysplasia (non-dysplastic, indefinite, low-grade, high-grade dysplasia, intramucosal carcinoma) - **Guides management**: dysplasia grade directly determines surveillance interval or intervention (endoscopic ablation/resection for HGD) **High-Yield:** Barrett's esophagus surveillance is a **classic NEET PG topic**. The key principle: **chromoendoscopy + targeted biopsies + dysplasia grading** is the standard of care per American College of Gastroenterology (ACG) and European guidelines. ### Barrett's Esophagus Dysplasia Grading and Management | Dysplasia Grade | Histology | Management | Surveillance Interval | |---|---|---|---| | Non-dysplastic Barrett's | Intestinal metaplasia only | Surveillance endoscopy | 3 years | | Indefinite for dysplasia | Cytologic atypia, unclear if dysplasia | Repeat endoscopy in 3 months | 3 months | | Low-grade dysplasia (LGD) | Nuclear enlargement, hyperchromasia, mild disorganization | Endoscopic ablation OR close surveillance | 3 months if no ablation | | High-grade dysplasia (HGD) | Marked nuclear atypia, loss of maturation, increased mitoses | **Endoscopic resection / ablation** (radiofrequency, cryotherapy) | 3 months post-treatment | | Intramucosal carcinoma | Invasion into lamina propria, no involvement of muscularis propria | Endoscopic resection or esophagectomy | Individualized | **Clinical Pearl:** Chromoendoscopy increases the detection of dysplasia by ~25% compared to white-light endoscopy alone. In a patient with Barrett's esophagus and no visible nodularity, chromoendoscopy is essential to identify subtle dysplastic areas. ### Mnemonic for Barrett's Esophagus Surveillance **CHROME-BIOPSY** = **CHROMoEndoscopy + targeted BIOPsY** is the standard approach for dysplasia detection in Barrett's esophagus. **Warning:** Do not confuse chromoendoscopy (a technique to enhance visualization and guide biopsies) with the diagnosis itself. The **diagnosis of dysplasia is histopathological**, not endoscopic.